Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) statesTakeshi Yoshida, Junji Matsui|British Journal of Cancer|2014Cited by 355
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Kenya Hayashi et al.|Annals of Oncology|2017Cited by 294
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumorsToshio Shimizu, Kazuhiko Nakagawa, Kazuya Fukuoka et al.|Cancer Chemotherapy and Pharmacology|2016Cited by 109
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung CancerTakeshi Yoshida, Eric B. Haura|PLoS ONE|2016Cited by 98
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid TumorsMasayuki Takeda, Kazuto Nishio, Takayuki Takahama et al.|The Oncologist|2020Cited by 95